



2023-2024 Interim COVID-19 and Nirsevimab Vaccine Borrowing Policy


For the 2023-2024 COVID-19 and Nirsevimab respiratory virus season, the Georgia Immunization Program (GIP) has adopted the Centers for Disease Control and Prevention’s (CDC’s), approved, two-way or bidirectional borrowing policy. Two-way borrowing will allow providers to administer state supplied COVID-19 vaccine and nirsevimab to fully insured children and adults or to administer privately purchased COVID-19 vaccine and nirsevimab to VFC eligible children and uninsured or underinsured adults in the event there is a delay in shipment of either stock. The purpose of this policy is to prevent missed COVID-19 vaccine and nirsevimab administration opportunities for both VFC/AVP-eligible and fully insured patients. The amount of COVID-19 vaccine and nirsevimab that can be borrowed is not limited to a certain amount, however, as with other VFC/AVP vaccine products, the borrowing policy does not alleviate a provider’s responsibility to appropriately order, in a timely manner, enough private COVID-19 vaccine and nirsevimab to vaccinate insured patients within the practice.

The bidirectional COVID-19 vaccine and nirsevimab borrowing policy may not be used as a replacement system for a provider’s privately purchased vaccine inventory. Providers must ensure borrowing state supplied COVID-19 vaccine and nirsevimab to immunize a fully insured patient does not prevent an eligible patient from receiving a needed COVID-19 vaccine and nirsevimab. Providers agree to follow all VFC/AVP requirements, which include screening patients for eligibility at each immunization encounter and documenting their eligibility status.

COVID-19 and Nirsevimab Vaccine Replacement of Borrowed Doses (Provider Responsibilities):

- Physically transfer the COVID-19 vaccine and nirsevimab you are replacing in your refrigerator (e.g., moving the vaccine from private supply to state supply or from state supply to private supply)
- Complete the DPH Vaccine Borrowing Report and submit with your Monthly Comprehensive Report
- Replace borrowed doses with the same type of product (does NOT have to be the same brand), covering the same administration indications.
- Every attempt should be made to replace borrowed doses within 30 days.

The GA Immunization Program will allow two-way borrowing of COVID-19 and Nirsevimab product types as shown below:



<p>VFC Supply COVID-19(Moderna);(6m-11y);SDV;10-pk</p>		<p>Private Purchase Supply COVID-19(Moderna);(6m-11y);SDV;10-pk</p>
<p>VFC/AVP Supply (COMIRNATY) COVID-19;(12y+);SDV;10-pk</p>		<p>Private Purchase Supply (COMIRNATY) COVID-19;(12y+);SDV;10-pk</p>
<p>VFC Supply COVID-19(Pfizer);(5y-11y);SDV;10-pk</p>		<p>Private Purchase Supply COVID-19(Pfizer);(5y-11y);SDV;10-pk</p>
<p>VFC Supply COVID-19(Pfizer);(6m-4y);MDV3;10-pk</p>		<p>Private Purchase Supply COVID-19(Pfizer);(6m-4y);MDV3;10-pk</p>
<p>VFC Supply Nirsevimab (Beyfortus)</p>		<p>Private Purchase Supply Nirsevimab (Beyfortus)</p>

If you have any questions or need assistance, please contact our office at (800) 848-3868 or send an email to DPH-gavfc@dph.ga.gov.